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Background: An important parameter for survival in patients with esophageal carcinoma is lymph node status. The
distribution of lymph node metastases depends on tumor characteristics such as tumor location, histology, invasion
depth, and on neoadjuvant treatment. The exact distribution is unknown. Neoadjuvant treatment and surgical
strategy depends on the distribution pattern of nodal metastases but consensus on the extent of
lymphadenectomy has not been reached. The aim of this study is to determine the distribution of lymph node
metastases in patients with resectable esophageal or gastro-esophageal junction carcinoma in whom a
transthoracic esophagectomy with a 2- or 3-field lymphadenectomy is performed. This can be the foundation for a
uniform worldwide staging system and establishment of the optimal surgical strategy for esophageal cancer
patients.
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Methods: The TIGER study is an international observational cohort study with 50 participating centers. Patients
with a resectable esophageal or gastro-esophageal junction carcinoma in whom a transthoracic
esophagectomy with a 2- or 3-field lymphadenectomy is performed in participating centers will be included.
All lymph node stations will be excised and separately individually analyzed by pathological examination. The
aim is to include 5000 patients. The primary endpoint is the distribution of lymph node metastases in
esophageal and esophago-gastric junction carcinoma specimens following transthoracic esophagectomy with
at least 2-field lymphadenectomy in relation to tumor histology, tumor location, invasion depth, number of
lymph nodes and lymph node metastases, pre-operative diagnostics, neo-adjuvant therapy and (disease free)
survival.
Discussion: The TIGER study will provide a roadmap of the location of lymph node metastases in relation to
tumor histology, tumor location, invasion depth, number of lymph nodes and lymph node metastases, pre-
operative diagnostics, neo-adjuvant therapy and survival. Patient-tailored treatment can be developed based
on these results, such as the optimal radiation field and extent of lymphadenectomy based on the primary
tumor characteristics.
Trial registration: NCT03222895, date of registration: July 19th, 2017.
Keywords: Esophageal cancer, Lymph node metastases, Lymphadenectomy, Esophagectomy,Background
Survival rates following an esophageal resection for
esophageal carcinoma vary from a median of 25 to 74
months [1, 2]. An important parameter for survival is
lymph node status [3–12]. The distribution of lymph
node metastases depends on tumor characteristics such
as tumor location, histology, invasion depth, and on neo-
adjuvant treatment [13–20]. However, the precise distri-
bution pattern is unknown.
In the Netherlands, among other countries, curative
treatment for patients with esophageal carcinoma con-
sists of neoadjuvant chemoradiation followed by surgery
[21, 22]. The radiation field during neoadjuvant treat-
ment and the lymphadenectomy during surgery depend
on the location of lymph node metastases but no con-
sensus has been reached on the extent of the lymphade-
nectomy [23]. If a distribution pattern of lymph node
metastases of esophageal carcinoma can be identified,
the optimal neoadjuvant and surgical treatment can be
determined.
The administration of neoadjuvant therapy itself can
also influence the distribution of lymph node metastases
[13]. Neoadjuvant chemoradiation may be able to
sterilize metastatic lymph nodes. Lymph nodes inside
the radiation field are affected by both radiotherapy and
concurrent chemotherapy, whereas lymph nodes outside
the radiation field are affected by chemotherapy only.
Nevertheless, recent studies show that also after neoad-
juvant therapy, the extend of lymphadenectomy is dir-
ectly related to survival [24]. Therefore, not only the
metastatic behavior of untreated esophageal carcinoma
is an important factor, also the pattern after neoadjuvant
therapy can provide valuable information for the optimal
extend of lymphadenectomy after chemo (radio)therapy.Especially for adenocarcinoma the distribution of
lymph node metastases has not yet been described in
large series that report on a complete 2- or 3-field
lymphadenectomy [13, 14]. Also, different classification
systems for lymph node stations are used in current lit-
erature, leading to incomparable studies. Besides the
limited and heterogeneous evidence, also the significant
morbidity involved in esophageal surgery makes the
treatment choices demanding considering that the re-
moval of more lymph nodes may lead to a more invasive
procedure, possibly increasing the risk for postoperative
morbidity.
A large observational study could identify lymph node
stations that should be resected in relation to tumor
characteristics and may clarify if the same surgical strat-
egy is justified in patients with and without neoadjuvant
therapy. Furthermore, the prognostic value of different
lymph node stations can be established. We thus
propose a multicenter prospective study to determine
the distribution of lymph node metastases in patients
with resectable esophageal or gastro-esophageal junction
carcinoma in whom a transthoracic esophagectomy with
a 2- or 3-field lymphadenectomy is performed. This can
be the foundation for a uniform worldwide staging sys-
tem and establishment of the optimal surgical strategy
for esophageal cancer patients.Methods
Objective
The aim of the TIGER study is to evaluate the distribu-
tion of lymph node metastases in esophageal carcinoma
specimens following transthoracic esophagectomy with a
2- or 3- field lymphadenectomy.
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TIGER is an international observational cohort study.
The duration of the study will approximately be 7 years
(2 years inclusion, 5 years follow-up). There are currently
50 participating centers distributed over 18 countries.
Centers are located in The Netherlands (10), Sweden (1),
Finland (1), Belgium (2), Germany (3), Swiss (1), France
(1), Italy (5), Spain (2), United Kingdom (7), Ireland (2),
Japan (4), Hong Kong (1), China (1), India (2), United
States (5), Canada (1) and Brazil (1). Data from each par-
ticipating hospital will be collected at the TIGER website
(www.tigerstudy.net). Data collection forms can be
assessed after login on the website. Each hospital has ac-
cess to their own dataset.
Study population
All patients with a resectable (cT1-4a, N0–3, M0)
esophageal or gastro-esophageal junction carcinoma.
Inclusion criteria
In order to be eligible to participate in this study, a sub-
ject must meet all of the following criteria:
 Primary squamous cell or adenocarcinoma of the
esophagus or esophago-gastric junction
 Surgically resectable tumor (cT1-4a, N0–3, M0)
 Adequate physical condition to undergo
transthoracic surgery (ASA 1–3)
 Transthoracic esophagectomy, either open or
minimal invasive
Exclusion criteria
A potential subject who meets any of the following cri-
teria will be excluded from participation in this study:
 Previous thoracic or abdominal (upper GI) surgery
disturbing lymph drainage of the esophagus and
stomach
 Patients with in situ carcinoma or high-grade
dysplasia
Sample size
The aim is to include 5000 patients. This number suf-
fices for descriptive purposes and clustering of metasta-
ses diffusion profiles into meaningful subgroups within
predefined strata (patients with adenocarcinoma or
squamous cell carcinoma, with and without neoadjuvant
therapy, different tumor heights and invasion depths,
and following a 2- or 3-field lymphadenectomy). In
2012, the incidence of esophageal cancer was 456.000
new cases worldwide [25]. Only a small percentage of
patients with esophageal cancer present with curable
disease at time of diagnosis. The aim is to include all5000 patients with resectable disease in the 50 partici-
pating centers in a 2-year time period.
Primary endpoint
The distribution of lymph node metastases in esopha-
geal and esophago-gastric junction carcinoma speci-
mens following transthoracic esophagectomy with at
least 2-field lymphadenectomy in relation to tumor
histology, tumor location, invasion depth and neoad-
juvant therapy.
Secondary endpoints
 Accuracy of preoperative diagnostics (EUS and PET-
CT) and added value of EBUS to existing staging
with EUS/PET-CT
 Prognostic value of different lymph node stations
 Postoperative morbidity (anastomotic leakage, chyle
leakage, pneumonia, recurrent nerve injury and
arrhythmia)
 30-days/in-hospital and 90-days mortality
 3- and 5-year overall and disease-free survival
 Distribution pattern of recurrence or metastases In-field- or out-field nodal recurrence in case of
neo-adjuvant chemoradiation
 Number of harvested lymph nodes in patients who
are treated with and without neo-adjuvant chemo
(radio)therapy
 Analysis of the phenomenon skip nodal metastases
 Ratio of nodal metastases inside and outside the
radiation field
Treatment of subjects
Staging
Preoperative staging will be performed according to na-
tional guidelines. This therefore, may differ per country.
Usually, patients are staged with an endoscopy with bi-
opsies, an endoscopic ultrasound, a PET-CT-scan of
neck, thorax and abdomen and an ultrasound of the
neck. An EBUS-TBNA will be performed if indicated.
All patients are discussed in a multidisciplinary team
(MDT).
A suspected lymph node is defined as a node larger
than > 9mm short axis or a node 5–9 mm short axis
that is round, inhomogeneous and has an irregular
border (2 out of 3). In case of PET-CT-scan, pathological
nodes are those with FDG uptake, a short axis > 10mm
or those with a short axis between 5 and 9mm that
present with sharp borders.
Neoadjuvant therapy
In case of potentially curative disease (cT1-4a, N0–3,
M0) patients may be treated with neoadjuvant therapy,
Fig. 1 Classification of lymph node stations.
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of chemotherapy or chemoradiotherapy.
Radiation fields
One coronal, 1 sagittal and 3 axial CT-images of the ra-
diation field is documented in the medical file, to assess
lymph nodes stations incorporated in the radiation field.
An anatomical description of the radiation field will be
given according to highest and lowest radiated lymph
node station. An in-field lymph node is defined as a
lymph node within the clinical target volume. Clinical
target volume fields as defined gross tumor volume plus
a margin for sub-clinical disease spread.
Restaging
After completion of neoadjuvant therapy patients will
generally be restaged with a (PET-)CT scan to exclude
distant metastases before patients are scheduled for sur-
gery. In addition, the locoregional lymph nodes will be
evaluated. The (PET-)CT will usually be performed 2–4
weeks after completion of neoadjuvant therapy.
Surgery
If no metastases are detected, patients will be operated
5–12 weeks after completion of neoadjuvant therapy.
This may differ per country and may depend on the type
of neoadjuvant therapy. If no neoadjuvant therapy is ad-
ministered patients are directly scheduled for surgery.
An esophageal resection with a 2- or 3-field lymphade-
nectomy can be performed via a thoracolaparoscopy, a
thoracolaparotomy or a hybrid procedure and a cervical
incision as indicated. A gastric tube or colonic interpos-
ition can be used for reconstruction. Lymph node sta-
tions may be dissected ex vivo (after enbloc resection
with the specimen), in vivo, or partially ex and in vivo,
and will be separately sent for pathological examination.
Lymph node stations in close proximity to the tumor are
preferably marked with sutures or beads to prevent dam-
age to the specimen and circumferential resection
margin.
Lymph node classification systems
Different classification systems are used in different
countries to classify lymph node stations around the
esophagus: the AJCC 8th edition esophageal cancer sta-
ging and the JES 11th edition esophageal cancer staging.
In Fig. 1 and Table 1 these classifications have been
combined for the purpose of this study.
In case of a 3-field lymphadenectomy stations 1–19
will be resected and in case of a 2-field lymphadenec-
tomy stations 6–19 will be resected as usual. If not all
lymph node stations are resected, patients can still be in-
cluded in the study, however this has to be documented
accurately. A video appendix and definitions of the
Table 1 Classification of lymph node stations
Cervical lymph node stations (based on the JES 11th edition esophageal cancer
staging)
1. Superficial cervical lymph nodes
• Lymph nodes located along the external jugular veins and anterior jugular
veins beneath the superficial cervical fascia.
• Lymph nodes located around the submandibular glands and parotid glands,
and anterior to the mylohyoid muscle.
• Lymph nodes located in the pretracheal fatty tissue, extending from the hyoid
bone superiorly, to the left brachiocephalic vein inferiorly, including the
prethyroidal lymph nodes and the prelaryngeal lymph nodes.
• Lymph nodes located along the accessory nerve(s), and anterior to the
trapezius muscle.
2. Cervical paraesophageal lymph nodes
• Lymph nodes located around the cervical esophagus, including lymph nodes
located along the recurrent laryngeal nerve and the cervical paratracheal lymph
nodes. The lateral boundary is the medial border of the carotid sheath.
3. Deep cervical lymph nodes
• Lymph nodes located around the internal jugular vein and the common
carotid artery.
• Lymph nodes located from the caudal border of the digastric muscle superior
to the carotid artery bifurcation.
• Lymph nodes located from the carotid artery bifurcation superiorly to the
lower border of the cricoid cartilage inferiorly.
4. Peripharyngeal lymph nodes
• Lymph nodes located medial to the carotid sheath, extending from the caudal
border of the digastric muscle superiorly to the lower border of the cricoid
cartilage inferiorly. Postpharyngeal and parapharyngeal lymph nodes are
included.
5. Supraclavicular lymph nodes
• Lymph nodes located in the supraclavicular fossa, extending from the lower
border of the cricoid cartilage superiorly, to the clavicle inferiorly, including the
lower internal deep cervical lymph nodes. The medial boundary is the medial
border of the carotid sheath.
Thoracic lymph node stations (based on the JES 11th edition esophageal cancer
staging and the AJCC 8th edition esophageal cancer staging)
6. Upper paratracheal lymph nodes (right / left)
• Right: Lymph nodes located around the upper thoracic esophagus posterior
to the right vagal nerve. Lymph nodes located along the anterior and lateral
wall of the thoracic trachea until the level of the right vagal nerve. Lymph
nodes located along the right recurrent laryngeal nerve in the mediastinum.
The superior boundary is drawn from the cephalic border of the right
subclavian artery to the suprasternal notch.
• Left: Lymph nodes located around the upper thoracic esophagus. Lymph
nodes located along the anterior and lateral wall of the thoracic trachea until
the upper margin of the aortic arch. Lymph nodes located along the left
recurrent laryngeal nerve in the mediastinum. The superior boundary is drawn
from the cephalic border of the left subclavian artery to the suprasternal notch.
7. Lower paratracheal lymph nodes (right / left)
• Right: Lymph nodes located in the tracheobronchial angle and located along
the anterior and lateral wall of the thoracic trachea. The superior boundary is
the vagal nerve, the ventral boundary the superior caval vein.
• Left: Lymph nodes located in the tracheobronchial angle and located along
the anterior and lateral wall of the thoracic trachea. Lymph nodes located
along the azygos vein arch and the right bronchial artery are included. Lymph
nodes along the proximal part of the left recurrent laryngeal nerve along the
aortic arch are also included. The superior boundary is the inferior wall of the
aortic arch, and the lymph nodes are located in the area surrounded by the
medial wall of the aortic arch.
8. Aortopulmonary window lymph nodes
• Subaortic and para-aortic nodes lateral to the ligamentum arteriosum. Superior
boundary is the lower margin of the aortic arch. Ventral boundary is the pul-
monary artery, distal boundary the left main bronchus.
9. Subcarinal lymph nodes
• Lymph nodes located caudal to the carina of the trachea. The lateral
boundaries are the extended line of both lateral margins of the trachea.
10. Upper mediastinal paraesophageal lymph nodes
Table 1 Classification of lymph node stations (Continued)
• Dissection of the lymph nodes located around the upper thoracic esophagus.
From the thoracic aperture until the trachea bifurcation.
11. Middle mediastinal paraesophageal lymph nodes
• Lymph nodes located around the middle thoracic esophagus. From the
trachea bifurcation to the caudal margin of the inferior pulmonary vein.
12. Lower mediastinal paraesophageal lymph nodes
• Lymph nodes located around the lower thoracic esophagus. From the caudal
margin of the inferior pulmonary vein to the esophagogastric junction
13. Pulmonary ligament lymph nodes (right / left)
• Right: Dissection of the lymph nodes within the right inferior pulmonary
ligament.
• Left: Dissection of the lymph nodes within the left inferior pulmonary
ligament.
Abdominal lymph node stations (based on the JES 11th edition esophageal
cancer staging ans the AJCC 8thedition esophageal cancer staging)
14. Paracardial lymph nodes (right / left)
• Right: Lymph nodes located immediately adjacent to the gastroesophageal
junction, including those along the first branch of the ascending limb of the
left gastric artery.
• Left: Lymph nodes located immediately adjacent to the gastroesophageal
junction, including those along the esophagocardiac branch of the left
subphrenic artery
15. Left gastric artery lymph nodes
• Lymph nodes along the course of the left gastric artery. Superior boundary is
the caudal border of the first branch of the ascending limb of the left gastric
artery. Proximal boundary is the origin of the left gastric artery.
16. Celiac trunk lymph nodes
• Lymph nodes located around the celiac trunk. Dorsal boundary is the aorta;
ventral boundary is the origin of the left gastric artery.
17. Splenic artery and splenic hilum lymph nodes
• Lymph nodes from the origin of the splenic artery along its course alongside
the pancreatic tail, including those adjacent to the splenic artery distal to the
pancreatic tail, and those on the roots of the short gastric arteries and those
along the left gastroepiploic artery proximal to its 1st gastric branch.
18. Common hepatic artery lymph nodes
• Lymph nodes from the origin of the common hepatic artery along its course
until the division into the gastroduodenal and proper hepatic artery.
19. Hepatoduodenal ligament lymph nodes
• Lymph nodes along the proper hepatic artery and along the portal vein in the
caudal half between the confluence of the right and left hepatic ducts and the
upper border of the pancreas.
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able for review on the TIGER study website.
Pathology
The esophageal resection and lymphadenectomy speci-
mens will be processed and analyzed according to na-
tional and international guidelines by the department of
pathology. In addition to the separately sent lymph node
stations, the esophageal surgical resection specimen will
be carefully analyzed for retained lymph nodes and
structures macroscopically suspicious for lymph nodes
will be embedded. All lymph nodes under 5 mm will be
totally embedded for microscopic evaluation, larger
lymph nodes will be totally embedded in slices of 3–4
mm thick. Microscopically, a circumscript area of
lymphoid cells containing a follicular architecture and/or
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final report the exact localization and number of lymph
nodes found will be reported.
Initial microscopic evaluation will be performed by
standard H&E staining. In case of suspicion of micro-
metastasis (0.2–2.0 mm) or isolated tumor cells in the
lymph node, or in case of suspicion of residual tumor
cells in patients with extensive response to neoadjuvant
therapy, additional keratin stains will be performed. A
metastatic lymph node is defined as a lymph node with
tumor cells. Lymph nodes containing micro-metastasis
or isolated tumor cells are also considered as metastatic
lymph nodes but will be also recorded separately. Lymph
nodes with regression after chemoradiation with isolated
tumor cells will be considered as metastatic lymph
nodes, however, these also will be recorded separately,
so that the prognostic value of these isolated tumor cells
can be determined. The same applies to fibrotic lymph
nodes without vital tumor cells. These are so called pre-
neoadjuvant therapy N+ nodes. In case of an adenocar-
cinoma of the esophagus, Her2-status will be analyzed
(immunohistochemistry and SISH).
Follow-up
Patients will be followed up until 5 years after the oper-
ation. Follow-up will usually be scheduled (but differ-
ences between countries exist) every 3 months the first
year, every 6 months the second until the fourth year
and once yearly until the fifth year. Investigations are
performed according to national guidelines.
Statistical analysis
Primary study parameter(s)
Numbers and percentages of resected lymph nodes and
lymph node metastases will be given per lymph node
station (Fig. 1). Tumor location and invasion depth will
be categorized. Patients with adenocarcinoma and squa-
mous cell carcinoma and patients with and without neo-
adjuvant therapy will be analyzed separately.
Secondary study parameter(s)
The sensitivity, specificity, and positive and negative pre-
dictive values of EUS and PET-CT will be reported. Peri-
operative morbidity and mortality will be summarized
descriptively. For each patient group (squamous cell ver-
sus adenocarcinoma, with and without neoadjuvant ther-
apy), explorative cluster analyses will be performed to
identify subgroups of patients with different patterns of
lymph nodes metastases. Potentially relevant characteris-
tics at the time of surgery like age, gender, tumor loca-
tion, tumor invasion depth, tumor differentiation, vaso-
invasive growth will be included in the analysis. No re-
strictions will be applied to the number of clusters in
each analysis, but the ratio of the largest cluster size tothe smallest cluster size should preferably not exceed the
value of 3 and/or the smallest cluster size should be
minimally 30 patients. Characteristics introducing pa-
tient outliers will be excluded and one should further be
able to attribute meaning to the resulting cluster pro-
files. Clusters that show the phenomenon of skip metas-
tases will be noted. The resulting clusters will be
evaluated for the diffusion pattern of future metastases
during follow-up (descriptive analysis), the number of
future metastases during follow-up (Poisson regression
or generalized estimation equation, whichever appropri-
ate), for 3- and 5-year overall and disease-free survival
(Kaplan-Meier survival analysis). Multivariate analysis
will be performed using the Cox hazard regression
method. The univariate analysis, including all baseline
parameters, will serve as the basis for the multivariate
Cox hazard regression model. Variables showing associ-
ation (p < 0.10) with survival in univariate analysis will
be included in the multivariate analysis. Age and sex will
be included in all multivariate analyses. Results are pre-
sented as hazard ratio with exact 95% confidence inter-
val (95% CI). After 5-years of follow-up the efficacy
index will be determined (incidence of metastases to an
area (%) × 5-year overall survival rate (%)). A log-rank
test, Mann-Whitney U test, or χ2-test will be used as in-
dicated to compare groups. A value of p < 0.05 will be
considered statistically significant.
Discussion
The TIGER study is an international observational co-
hort study, with participation of worldwide renowned
esophageal cancer centers, that will investigate the distri-
bution of lymph node metastases is esophageal cancer.
This global study group will be a unique international
collaboration that will determine the pattern of lymph
node metastases in both squamous cell and adenocarcin-
oma, since, especially in adenocarcinoma, this has not
been investigated in multicenter prospective series be-
fore [11, 12]. The results of the TIGER study will pro-
vide a roadmap of the location of lymph node
metastases in relation to tumor histology, tumor loca-
tion, tumor invasion depth, number of lymph nodes and
lymph node metastases, pre-operative diagnostics, neo-
adjuvant therapy and survival. In addition, it will be in-
vestigated whether neoadjuvant chemoradiotherapy and
chemotherapy influence the presence and location of
lymph node metastases, as some recent reports suggest
that lymph nodes can become sterile after neoadjuvant
treatment and only fibrosis is found in these lymph
nodes [22]. The prognostic value of positive lymph
nodes, micrometastases, isolated tumor cells and fibrosis
will be investigated. Patient-tailored treatment can be
developed on the basis of the TIGER study results, such
as the optimal radiation field and the extent of the
Hagens et al. BMC Cancer          (2019) 19:662 Page 7 of 8lymphadenectomy and, additionally, it may aid in the de-
velopment of a global uniform classification system.
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